Therefore, SALL2 could be a potential target in tamoxifen‐resistant breast cancer in the future, as it is currently not possible to clinically upregulate SALL2 via transferring SALL2 cDNA into breast tumors. The gene discussed is SALL2; the disease is breast carcinoma.